IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
IceCure Appoints Meir Peleg as Chief Financial Officer
Icecure Medical Ltd (ICCM) Q4 2025 Earnings Call Highlights: Record Sales and Strategic U.S. ... [Yahoo! Finance]
IceCure Medical (ICCM) Q4 2025 Earnings Transcript [Yahoo! Finance]